FDA ordered Endo Pharma to remove opioid painkiller Opana ER from market — 4 insights

The FDA ordered Endo Pharmaceuticals to remove its opioid painkiller Opana ER from the market after concerns over potential abuse, CNN reports.

Advertisement

Here’s what you should know:

1. FDA Commissioner Scott Gottlieb, MD, said to CNN that the agency is taking action to remove the medication if its potential risks outweigh its benefits.

2. Opana ER contributed to a HIV outbreak among an Indiana-based addict population in 2015, CNN reports. HIV spread among the addicts who were sharing a needle to inject Opana into their bloodstream.

3. The drug is approximately two times as powerful as OxyContin.

4. The FDA originally approved Opana in 2006.

More articles on quality:
North America leading the way in the infection control market: 5 things to know
Toxic anterior segment syndrome in ASCs: 4 notes
Yelp, Vitals, Healthgrades physician ratings don’t match quality scores: 5 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.